Vicini, Paolo
Confo Therapeutics,
Belgium
2025 Rank: 213373
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Biomedical Engineering
Rank in SubField 1: 2072 out of 157499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 213373 | 202008 |
| Total Cites | 4760 | 5810 |
| H-index | 37 | 43 |
| Hm-index | 15 | 16 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 33 | 34 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 483 | 611 |
| Number of Single+First+Last Authored Papers | 81 | 81 |
| Total Cites to Single+First+Last Authored Papers | 1356 | 1643 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4254 | 4929 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.18 |
| Self-Citation Percentage |
18.07%
|
|
Vicini, Paolo
Confo Therapeutics,
Belgium
2024 Rank: 206266
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Biomedical Engineering
Rank in SubField 1: 2021 out of 148458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 206266 | 196124 |
| Total Cites | 4451 | 5478 |
| H-index | 36 | 41 |
| Hm-index | 15 | 16 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 32 | 33 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 468 | 596 |
| Number of Single+First+Last Authored Papers | 81 | 81 |
| Total Cites to Single+First+Last Authored Papers | 1292 | 1574 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3975 | 4633 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.18 |
| Self-Citation Percentage |
18.75%
|
|
Vicini, Paolo
AstraZeneca,
United Kingdom
2023 Rank: 203374
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Biomedical Engineering
Rank in SubField 1: 2047 out of 140593 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 203374 | 193479 |
| Total Cites | 4142 | 5131 |
| H-index | 34 | 39 |
| Hm-index | 14 | 16 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 32 | 33 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 453 | 578 |
| Number of Single+First+Last Authored Papers | 81 | 81 |
| Total Cites to Single+First+Last Authored Papers | 1212 | 1488 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3698 | 4336 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.18 |
| Self-Citation Percentage |
19.27%
|
|
Vicini, Paolo
AstraZeneca,
United Kingdom
2022 Rank: 193111
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Biomedical Engineering
Rank in SubField 1: 1969 out of 134745 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 193111 | 189216 |
| Total Cites | 3813 | 4740 |
| H-index | 33 | 37 |
| Hm-index | 14 | 15 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 31 | 32 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 441 | 556 |
| Number of Single+First+Last Authored Papers | 78 | 78 |
| Total Cites to Single+First+Last Authored Papers | 1141 | 1400 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3399 | 4003 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.18 |
| Self-Citation Percentage |
19.56%
|
|
Vicini, Paolo
AstraZeneca,
United Kingdom
2021 Rank: 188889
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Biomedical Engineering
Rank in SubField 1: 1945 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 188889 | 184468 |
| Total Cites | 3663 | 4567 |
| H-index | 32 | 36 |
| Hm-index | 14 | 14 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 31 | 32 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 432 | 548 |
| Number of Single+First+Last Authored Papers | 77 | 77 |
| Total Cites to Single+First+Last Authored Papers | 1098 | 1351 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3261 | 3854 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.19 |
| Self-Citation Percentage |
19.79%
|
|
Vicini, Paolo
MedImmune Limited, Cambridge,
United Kingdom
2020 Rank: 182523
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Biomedical Engineering
Rank in SubField 1: 1774 out of 94611 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 182523 | 178820 |
| Total Cites | 3260 | 4099 |
| H-index | 30 | 34 |
| Hm-index | 13 | 14 |
| Number of Single Authored Papers | 7 | 7 |
| Total Cites to Single Authored Papers | 31 | 32 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 402 | 516 |
| Number of Single+First+Last Authored Papers | 76 | 76 |
| Total Cites to Single+First+Last Authored Papers | 1014 | 1250 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 2915 | 3468 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.18 |
| Self-Citation Percentage |
20.47%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.